Inhibitors of checkpoint kinases: from discovery to the clinic.
Checkpoint kinase 1 (CHK1) is a member of the serine/ threonine kinase family. CHK1 functions as a regulatory kinase in cell-cycle progression and is the main effector of theDNA-damage response within the cell. Over the past few years, a large number of novel inhibitors of CHK1 have been discovered that encompass an enormous area of chemical space and diversity and, in more recent reports, many of these inhibitors have been demonstrated preclinically to sensitize tumors to a wide variety of DNA-damaging agents. This review focuses on advances reported both in the literature and at conferences from 2005 to date concerning the chemical design and optimization of checkpoint kinase inhibitors for the treatment of cancer.
AstraZeneca R&D Boston, Waltham, MA 02451, USA. James.Janetka@astrazeneca.com
James W
JW
Janetka
Susan
S
Ashwell
Sonya
S
Zabludoff
Paul
P
Lyne
D000818:Animals; D000071877:Checkpoint Kinase 1; D004249:DNA Damage / Q000187:drug effects; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011494:Protein Kinases / Q000187:drug effects*; D013329:Structure-Activity Relationship
D004791:Enzyme Inhibitors; D011494:Protein Kinases; C000605867:CHEK1 protein, human; D000071877:Checkpoint Kinase 1